Clinical Trial Update: Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating oral LBH589 (panobinostat) in patients with Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• LBH589 (panobinostat) (panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cutaneous T-Cell Lymphoma, Leukemia-Lymphoma, Adult T-Cell | Phase 2 | Status: TERMINATED